Sonnet BioTherapeutics (SONN) announced that its stockholders approved, among other things, the proposed business combination with Hyperliquid Strategies and Rorschach I at its special meeting of stockholders. The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SONN: